JP2017527561A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527561A5 JP2017527561A5 JP2017512320A JP2017512320A JP2017527561A5 JP 2017527561 A5 JP2017527561 A5 JP 2017527561A5 JP 2017512320 A JP2017512320 A JP 2017512320A JP 2017512320 A JP2017512320 A JP 2017512320A JP 2017527561 A5 JP2017527561 A5 JP 2017527561A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- formula
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 54
- 150000003839 salts Chemical class 0.000 claims 54
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- -1 4- (methylsulfonyl) phenyl Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004452 carbocyclyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020072573A JP6983273B2 (ja) | 2014-09-05 | 2020-04-14 | リジン特異的なデメチラーゼ−１の阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046842P | 2014-09-05 | 2014-09-05 | |
| US62/046,842 | 2014-09-05 | ||
| PCT/US2015/048429 WO2016037005A1 (en) | 2014-09-05 | 2015-09-03 | Inhibitors of lysine specific demethylase-1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020072573A Division JP6983273B2 (ja) | 2014-09-05 | 2020-04-14 | リジン特異的なデメチラーゼ−１の阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017527561A JP2017527561A (ja) | 2017-09-21 |
| JP2017527561A5 true JP2017527561A5 (enExample) | 2018-10-18 |
| JP6692350B2 JP6692350B2 (ja) | 2020-05-13 |
Family
ID=55440376
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512320A Expired - Fee Related JP6692350B2 (ja) | 2014-09-05 | 2015-09-03 | リジン特異的なデメチラーゼ−１の阻害剤 |
| JP2020072573A Expired - Fee Related JP6983273B2 (ja) | 2014-09-05 | 2020-04-14 | リジン特異的なデメチラーゼ−１の阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020072573A Expired - Fee Related JP6983273B2 (ja) | 2014-09-05 | 2020-04-14 | リジン特異的なデメチラーゼ−１の阻害剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9822119B2 (enExample) |
| EP (1) | EP3189038B1 (enExample) |
| JP (2) | JP6692350B2 (enExample) |
| KR (1) | KR102476459B1 (enExample) |
| CN (2) | CN112125901A (enExample) |
| AU (2) | AU2015311805B2 (enExample) |
| BR (1) | BR112017004334A2 (enExample) |
| CA (1) | CA2960188A1 (enExample) |
| CL (1) | CL2017000521A1 (enExample) |
| CO (1) | CO2017002191A2 (enExample) |
| EA (1) | EA201790376A1 (enExample) |
| EC (1) | ECSP17013466A (enExample) |
| ES (1) | ES2935114T3 (enExample) |
| IL (1) | IL250876B (enExample) |
| MX (1) | MX381597B (enExample) |
| SG (2) | SG10202008486SA (enExample) |
| WO (1) | WO2016037005A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112125901A (zh) * | 2014-09-05 | 2020-12-25 | 赛尔基因昆蒂赛尔研究公司 | 赖氨酸特异性脱甲基酶-1的抑制剂 |
| MX2017015922A (es) | 2015-06-12 | 2018-12-11 | Oryzon Genomics Sa | Biomarcadores asociados con inhibidores de lsd1 y usos de los mismos. |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| US10059668B2 (en) | 2015-11-05 | 2018-08-28 | Mirati Therapeutics, Inc. | LSD1 inhibitors |
| KR102204748B1 (ko) | 2015-11-27 | 2021-01-19 | 다이호야쿠힌고교 가부시키가이샤 | 신규 비페닐 화합물 또는 그의 염 |
| SG11201805645QA (en) | 2015-12-29 | 2018-07-30 | Mirati Therapeutics Inc | Lsd1 inhibitors |
| EP3429571B1 (en) | 2016-03-15 | 2025-10-08 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| JP2019512546A (ja) | 2016-03-16 | 2019-05-16 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CN105924397B (zh) * | 2016-04-29 | 2017-11-24 | 河南省农业科学院植物保护研究所 | 一种1,5‑二芳基‑3‑甲酸酯吡唑类化合物、制备方法及用途 |
| KR20210141778A (ko) * | 2016-06-07 | 2021-11-23 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| CN116478131A (zh) * | 2016-07-12 | 2023-07-25 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪 |
| EP3535420A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| KR102361918B1 (ko) * | 2017-05-26 | 2022-02-14 | 다이호야쿠힌고교 가부시키가이샤 | 신규 비페닐 화합물 또는 그의 염 |
| EP3632443B1 (en) * | 2017-05-26 | 2023-06-07 | Taiho Pharmaceutical Co., Ltd. | Anti-tumor effect potentiator using a biphenyl compound |
| MA50518A (fr) | 2017-05-31 | 2020-09-09 | Taiho Pharmaceutical Co Ltd | Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1 |
| BR112020000827A2 (pt) | 2017-08-03 | 2020-07-21 | Oryzon Genomics, S.A. | métodos de tratamento de alterações de comportamento |
| US20210393623A1 (en) | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
| PH12021552251A1 (en) | 2019-03-20 | 2022-07-25 | Oryzon Genomics Sa | Methods of treating borderline personality disorder |
| JP7535797B2 (ja) | 2019-03-20 | 2024-08-19 | オリソン ヘノミクス，ソシエダ アノニマ | 化合物バフィデムスタット（ｖａｆｉｄｅｍｓｔａｔ）などｋｄｍ１ａ阻害剤を使用した注意欠陥多動性障害の処置方法 |
| EP3986404A1 (en) | 2019-06-20 | 2022-04-27 | Celgene Quanticel Research, Inc. | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
| WO2021004610A1 (en) | 2019-07-05 | 2021-01-14 | Oryzon Genomics, S.A. | Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors |
| CA3157404A1 (en) | 2019-11-13 | 2021-05-20 | Taiho Pharmaceutical Co., Ltd. | Novel salt of terphenyl compound |
| TWI834127B (zh) * | 2021-03-11 | 2024-03-01 | 大陸商南京明德新藥研發有限公司 | 噻吩類化合物及其應用 |
| CN117062813A (zh) * | 2021-03-24 | 2023-11-14 | 四川汇宇制药股份有限公司 | 一种多环化合物及其应用 |
| BR112023020554A2 (pt) | 2021-04-08 | 2023-12-05 | Oryzon Genomics Sa | Combinações de inibidores de lsd1 para o tratamento de cânceres mieloides |
| US20250032454A1 (en) * | 2021-10-18 | 2025-01-30 | Imago Biosciences, Inc. | Kdm1a inhibitors for the treatment of disease |
| CN118206499A (zh) * | 2021-11-29 | 2024-06-18 | 郑州大学 | 一种2,3,5-三取代吡嗪类化合物及其制备方法和应用 |
| US20250163016A1 (en) * | 2022-01-25 | 2025-05-22 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Pyridine derivative, preparation method therefor and use thereof |
| CN116836167B (zh) * | 2022-03-25 | 2025-09-09 | 腾讯科技（深圳）有限公司 | 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途 |
| JP2025516647A (ja) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法 |
| CN119497613A (zh) | 2022-05-09 | 2025-02-21 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗nf1-突变肿瘤的方法 |
| EP4622635A1 (en) | 2022-11-24 | 2025-10-01 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| WO2024208187A1 (zh) * | 2023-04-03 | 2024-10-10 | 上海复星医药（集团）股份有限公司 | 氮杂芳基化合物及其作为lsd1抑制剂的用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6432975B1 (en) | 1998-12-11 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| JP2005500294A (ja) * | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ７に対するピリミジン阻害剤 |
| EP2316831B1 (en) | 2002-11-21 | 2013-03-06 | Novartis AG | 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer |
| CA2506568A1 (en) * | 2002-11-22 | 2004-06-10 | Merck & Co., Inc. | 2-[(4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists |
| EP1694670A1 (en) * | 2003-12-16 | 2006-08-30 | GPC Biotech AG | Pyrazine derivatives as effective compounds against infectious diseases |
| CA2560346A1 (en) * | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
| US20070078135A1 (en) * | 2005-04-18 | 2007-04-05 | Neurogen Corporation | Substituted heteroaryl CB1 antagonists |
| FR2896800B1 (fr) * | 2006-01-30 | 2008-04-11 | Servier Lab | Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| AR072845A1 (es) * | 2008-07-29 | 2010-09-22 | Boehringer Ingelheim Int | 5-alquil-pirimidinas y su uso en el tratamiento de enfermedades mediadas por la actividad de quinasas. |
| EP2258865A1 (en) | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer |
| RU2012132682A (ru) * | 2009-12-31 | 2014-02-10 | Пирамал Энтерпрайзис Лимитед | Ингибиторы диацилглицерин ацилтрансферазы |
| EP2560949B1 (en) | 2010-04-20 | 2015-12-02 | Università degli Studi di Roma "La Sapienza" | Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2 |
| EP2598480B1 (en) * | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| KR101351919B1 (ko) | 2012-05-23 | 2014-01-24 | 현대모비스 주식회사 | 차선 유지 보조 시스템 및 방법 |
| EP2925307B1 (en) | 2012-11-30 | 2020-10-28 | McCord, Darlene E. | Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition |
| AR098203A1 (es) | 2013-11-13 | 2016-05-18 | Dow Global Technologies Llc | Reactivo de ensayo de formaldehído |
| DK3080100T3 (da) * | 2013-12-11 | 2023-02-06 | Celgene Quanticel Res Inc | Hæmmere af lysinspecifik demethylase-1 |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| CN112125901A (zh) * | 2014-09-05 | 2020-12-25 | 赛尔基因昆蒂赛尔研究公司 | 赖氨酸特异性脱甲基酶-1的抑制剂 |
-
2015
- 2015-09-03 CN CN202011074135.4A patent/CN112125901A/zh active Pending
- 2015-09-03 KR KR1020177009066A patent/KR102476459B1/ko active Active
- 2015-09-03 CN CN201580059765.5A patent/CN107074787B/zh not_active Expired - Fee Related
- 2015-09-03 SG SG10202008486SA patent/SG10202008486SA/en unknown
- 2015-09-03 EA EA201790376A patent/EA201790376A1/ru unknown
- 2015-09-03 AU AU2015311805A patent/AU2015311805B2/en not_active Ceased
- 2015-09-03 CA CA2960188A patent/CA2960188A1/en active Pending
- 2015-09-03 ES ES15838524T patent/ES2935114T3/es active Active
- 2015-09-03 WO PCT/US2015/048429 patent/WO2016037005A1/en not_active Ceased
- 2015-09-03 BR BR112017004334A patent/BR112017004334A2/pt active Search and Examination
- 2015-09-03 US US14/845,120 patent/US9822119B2/en active Active
- 2015-09-03 EP EP15838524.5A patent/EP3189038B1/en active Active
- 2015-09-03 SG SG11201701683XA patent/SG11201701683XA/en unknown
- 2015-09-03 MX MX2017002824A patent/MX381597B/es unknown
- 2015-09-03 JP JP2017512320A patent/JP6692350B2/ja not_active Expired - Fee Related
-
2017
- 2017-03-01 IL IL250876A patent/IL250876B/en unknown
- 2017-03-03 EC ECIEPI201713466A patent/ECSP17013466A/es unknown
- 2017-03-03 CL CL2017000521A patent/CL2017000521A1/es unknown
- 2017-03-06 CO CONC2017/0002191A patent/CO2017002191A2/es unknown
- 2017-10-02 US US15/723,050 patent/US10543198B2/en not_active Expired - Fee Related
-
2019
- 2019-12-05 US US16/705,135 patent/US10864202B2/en active Active
-
2020
- 2020-04-14 JP JP2020072573A patent/JP6983273B2/ja not_active Expired - Fee Related
- 2020-06-26 AU AU2020204287A patent/AU2020204287A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527561A5 (enExample) | ||
| JP2017502940A5 (enExample) | ||
| JP2017519781A5 (enExample) | ||
| JP2017514830A5 (enExample) | ||
| EA201992884A2 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| JP2017521407A5 (enExample) | ||
| EA201590345A1 (ru) | Способы лечения рака с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона | |
| JP2017523152A5 (enExample) | ||
| JP2017513894A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
| BR112015021027A8 (pt) | compostos terapêuticos, seus usos, e composições farmacêuticas | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| JP2016522172A5 (enExample) | ||
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| JP2016515560A5 (enExample) | ||
| EA201691629A1 (ru) | Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения | |
| RU2017145930A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) | |
| JP2019510810A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| JP2016528273A5 (enExample) | ||
| JP2017501237A5 (enExample) | ||
| JP2014513051A5 (enExample) | ||
| JP2017527590A5 (enExample) |